BMS Pharmaceutical Korea has obtained permission for a series of blood cancer treatments this year, increasing its weight in the domestic market.Starting with a nod for the treatment of acute myeloid leukemia, Onureg (azacitidine), in March, it obtained approvals for Inreㅠic (pedratinib), a treatmen
AstraZeneca Korea and Abbott said they would collaborate to provide a more systemic treatment and management of diabetic kidney disease in Korea.The Korean unit of AstraZeneca and Abbott Rapid Diagnostics Korea signed a partnership agreement to improve the treatment environment for diabetic kidney d
Introducing immunotherapy Libtayo (cemiplimab-rwlc) in Korea, Sanofi has selected cutaneous squamous cell carcinoma (cSCC) as its primary indication, for which there are no competitive products.According to a domestic skin cancer epidemiological study published early this year, the incidence of cSCC
Pfizer's Ibrance (palbociclib), the first CDK4/6 inhibitor that rewrote the history of treating metastatic hormone receptor-positive/human epidermal growth factor receptor 2 negative (HR+/HER2-) breast cancer, seems to have failed to enter the early treatment market.Professor Angela DeMichele of the
Korean researchers developed a new treatment strategy for biliary tract cancer, which surpasses the GemCis (gemcitabine plus cisplatin) therapy, which has been the standard primary treatment over the past few decades and won global recognition.The U.S. Food and Drug Administration approved the combi
According to the latest report by UNAIDS, a U.N. agency exclusively responsible for AIDS, the number of new HIV infections worldwide totaled about 1.5 million in 2021, more than a million more than the global target.UNAIDS, which declared to terminate AIDS by 2030, puts its foremost priority on HIV
Enhertu (trastuzumab deruxtecan) and Trodelvy (sacituzumab govitecan), the two breast cancer therapies based on the next-generation antibody-drug conjugates (ADC), will likely take the lead in the cancer’s innovative treatment across the board.The first-generation ADC developed by Roche, Kadcyla (tr
Spinraza (nusinersen), the first spinal muscular atrophy (SMA) treatment that won the insurance coverage quickly since its introduction in Korea, is experiencing difficulty expanding its reimbursement standards.At stake is the “suspension of reimbursement” for SMA 3-type patients.There were four exp
The American Society of Clinical Oncology (ASCO) recently revised the guidance for the use of PARP inhibitor (PARPi) therapy in ovarian cancer, saying PARPi monotherapy is no longer recommended to treat recurrent platinum-sensitive epithelial ovarian cancer.Still, ASCO opened the possibility that PA
PARP inhibitors, which had emerged as the most common targeted therapy for unresectable ovarian cancer, could increase death risk in patients who experienced several chemotherapies, a recent study showed, forcing developers to withdraw their indications.AstraZeneca reportedly distributed an official
A recent study said that the risk of developing shingles increases among adults 50 and older with the experience of infection by Covid-19.A research team led by Dr. Amit Bhavsar, director of clinical research and development at GSK, released its research results on the incidence rate of shingles aft
Dupixent (dupilumab), the first approved biological drug for treating atopic dermatitis, has not just improved symptoms in oral corticosteroid-dependent asthma patients but demonstrated the effect of reducing steroid use.Sanofi said so, releasing its three-year, long-term data on severe asthma patie
Janssen’s Imbruvica (ibrutinib) and BeiGene’s Brukinsa (zanubrutinib), the two BTK (bruton tyrosine kinase) inhibitors with the same mechanism, received two different review results from the Health Insurance Review and Assessment Service’s (HIRA) cancer drug reimbursement review committee.The review
Drugmakers are gearing up to race in the development of a denosumab biosimilar to treat various bone diseases. Sandoz, a subsidiary of Novartis handling off-patent medicines, said on Monday that it confirmed positive results from a study of a proposed biosimilar denosumab (original brands: Prolia, X
PARIS -- “Lung cancer treatment is developing day by day, but the domestic health insurance benefits and other treatment environments fall far short of supporting the development.”Professor Ahn Myung-joo of the Department of Hemato-oncology at Samsung Medical Center (SMC) said so on Sunday when aske
PARIS – A Korean expert has given a positive evaluation to the phase 3 clinical trial results of VEGFR2 Tigit Tyrosine Kinase Inhibitor (TKI), “rivoceranib,” which proved effective in the first-line treatment of liver cancer combined with the anti-PD-1 immuno-cancer drug, "camrelizumab."Rivoceranib
A year has passed since Organon & Co. spun off from MSD, vowing to be a company specializing in the field of female healthcare.Over the past year, Organon has made positive efforts to promote female health. For instance, it acquired companies producing postpartum solutions to treat postpartum hyster
BARCELONA, Spain – AstraZeneca’s SGLT-2 inhibitor Forxiga (ingredient: dapagliflozin) proved its effectiveness in reducing cardiovascular death or heart failure (HF) in patients with a mildly reduced or preserved ejection fraction (EFmrEF or HFpEF) in phase 3 DELIVER study.Forxiga created new clinic
Breast cancer patients and their families increasingly demand the government’s quick approval for Enhertu (ingredient: trastuzumab deruxtecan), a new breast cancer treatment.On the online petition site of the National Assembly on Tuesday, a petitioner urged the government to approve Enhertu. It is t
Physicians are widely prescribing the antidiabetic drug metformin, antiparasitic drug ivermectin, and antidepressant fluvoxamine despite their insufficient evidence for Covid-19 treatment.However, in a randomized, placebo-controlled trial, U.S. researchers found that none of the three medicines coul